Spain Aiming to leverage European Union funds to reindustrialise its economy, the Spanish government has approved a public-private collaboration instrument to transform its health sector. The project looks to position Spain as a leader in precision medicine R&D and strengthen its healthcare sector with an investment of EUR 1.46 billion that…
Switzerland After 15 years as director at the Friedrich Miescher Institute for Biomedical Research (FMI) (2004-2019) and even longer as the group leader at her own research lab, Professor Susan M. Gasser was appointed director of the Foundation of the Swiss Institute for Experimental Cancer (ISREC), in a way closing the…
Switzerland Professor Susan M. Gasser, now director and group leader emeritus of the Friedrich Miescher Institute for Biomedical Research (FMI), shares the crucial aspects behind the FMI’s world-class reputation in basic research, her thoughts on the importance of public-private collaboration, and her perspectives on the European research ecosystem. Since February 1,…
Europe Dr Pierre Meulien, executive director of the Innovative Medicines Initiative (IMI), the world’s largest life science public-private partnership between the European Union and the European pharmaceutical industry, shares the incredible work IMI has been doing through the COVID-19 pandemic, along with the critical importance of public-private partnerships for areas like…
Brazil Swiss pharma giant Novartis is teaming up with the Oswaldo Cruz Foundation (Fiocruz) in Brazil to conduct research throughout Latin America on neglected diseases. This agreement establishes an exchange of know-how that will provide progress in public health policies in Brazil Patrice Matchaba, global head of corporate responsibility, Novartis…
Tunisia Jade Salhab, senior private sector development specialist at World Bank Tunisia, discusses the impact of the public-private dialogues initiated by his organization in Tunisia, and the additional measures needed to improve healthcare outcomes in Tunisia The World Bank, in response to a request from the government of Tunisia, facilitated a…
Colombia Sandra Cifuentes, General Manager of Astellas Farma Colombia, one of the most recent entrants in the Colombian market, explains the strategic priorities for establishing a strong position in the country, where the prime focus is on bringing a collaborative approach that can unite the industry towards a more sustainable healthcare…
Ukraine Alexander Boiko, general manager of Novo Nordisk Ukraine, provides insights into the recent progress and remaining room for improvement in Ukraine’s health capacity when it comes to preventing, diagnosing, and treating diabetes, as well as the company’s unique commitment to partner with the government at the moment an unprecedented set…
Indonesia Airlangga Hartarto, Indonesia’s minister of industry, explains the Ministry’s commitment to talent pool development, economic capital availability, and technology implementation within the national industrial landscape. Furthermore, he highlights the role of the governmental institution to create a positive ecosystem between the public and private stakeholders playing a role in the…
Indonesia Dr. Agus Prabowo, chairman at LKPP (the Indonesian National Public Procurement Agency) explains the importance of embracing technology to gain efficiency and effectiveness in the public procurement process of healthcare products as well as the outcomes from e-catalogue implementation in Indonesia. Could you please introduce the main activities of LKPP…
Mexico Aristides Torres, CEO at Laboratorios Vanquish, explains how the company has evolved during the last five years to serve both the public and private markets and why they have focused on niche market areas with high unmet patient need. Could you please give an update to our international audience about…
Italy Prof. Luca G. Guidotti discusses the esteemed positioning of San Raffaele within the global scientific community, their core mission of translational medicine and the challenges Italy faces today with the development of young scientific talent and the bridging of the public-private gap. Prof. Guidotti, could you begin by describing the…
See our Cookie Privacy Policy Here